Catalyst Pharmaceuticals (NASDAQ:CPRX) Sees Unusually-High Trading Volume – Should You Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) saw unusually-high trading volume on Thursday . Approximately 5,312,735 shares were traded during trading, an increase of 263% from the previous session’s volume of 1,464,761 shares.The stock last traded at $31.1250 and had previously closed at $30.52.

Trending Headlines about Catalyst Pharmaceuticals

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst for about $4.1 billion (USD 31.50 per share), a ~28% premium to recent VWAP; transaction was unanimously approved by both boards and is expected to close in Q3, creating a near-term cash floor for the stock. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD
• Positive Sentiment: Catalyst announced a settlement with Hetero Labs that licenses a generic FIRDAPSE to launch no earlier than January 2035 (pending FDA approval), resolving active patent suits and preserving FIRDAPSE exclusivity for the near–to–medium term. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: Zacks published a preview of CPRX’s Q1 results highlighting key metrics beyond headline EPS/revenue — useful for gauging whether the company’s latest commercial performance supports the valuation implied by the deal. Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
• Neutral Sentiment: Stephens reaffirmed an “equal weight” rating on CPRX, a non‑directional signal that suggests analysts view the acquisition price as reasonable relative to risk/reward but not a strong catalyst for a higher independent valuation. Benzinga
• Negative Sentiment: Two investor‑rights firms (Ademi LLP and Halper Sadeh LLC) have launched investigations into whether the $31.50 per‑share deal delivers a fair price to public shareholders — such actions can lead to litigation, delays, or demands for a higher bid. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
• Negative Sentiment: Halper Sadeh LLC separately announced an investigation into the sale to Angelini (same concern about deal fairness); this increases the chance of proxy litigation or settlement demands that could affect timing or economics of the close. CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
• Negative Sentiment: Recent insider sales reported in public filings (multiple officers sold shares in the past six months) may be viewed negatively by some investors, though sales can be routine and are occurring alongside a cash‑offer announcement. Catalyst Pharmaceuticals and Hetero Labs Ltd. Settle FIRDAPSE Patent Litigation

Wall Street Analysts Forecast Growth

CPRX has been the subject of several research reports. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Finally, Citigroup upped their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $33.33.

Catalyst Pharmaceuticals Price Performance

The company has a market capitalization of $3.81 billion, a PE ratio of 18.45, a PEG ratio of 1.00 and a beta of 0.72. The company has a 50 day moving average of $25.17 and a two-hundred day moving average of $23.85.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Deerfield Management Company L.P. grew its stake in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares during the period. Janus Henderson Group PLC grew its stake in shares of Catalyst Pharmaceuticals by 200.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after acquiring an additional 1,147,565 shares during the last quarter. Morgan Stanley grew its stake in shares of Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after acquiring an additional 1,089,775 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Catalyst Pharmaceuticals by 43.8% in the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after acquiring an additional 770,198 shares during the last quarter. Finally, Fundsmith LLP grew its stake in shares of Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after acquiring an additional 654,721 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).